- Home
- BMBL vs ALT Comparison
BMBL vs ALT Comparison
Compare BMBL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMBL | ALT |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.0M | 421.5M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BMBL | ALT |
|---|---|---|
| Price | $3.77 | $3.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $4.42 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 3.7M | 2.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $965,658,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $2.61 | $2.87 |
| 52 Week High | $8.63 | $7.73 |
Technical Indicators
Market Signals| Indicator | BMBL | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 42.47 |
| Support Level | $3.21 | $2.87 |
| Resistance Level | $3.85 | $4.25 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 97.73 | 60.45 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.